Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Richard Gaster
AddedMar 31, 2024
UpdatedMay 31, 2026
Richard Gaster

Richard Gaster

Board Member, Stargazer Pharmaceuticals

CrunchbaseLinkedIn

Richard Gaster's Career

Stargazer Pharmaceuticals
Stargazer Pharmaceuticals

Boston, MA, US

Board Member· Board
Aeovian Pharmaceuticals
Aeovian Pharmaceuticals

San Francisco, CA, US

Board Member· Board
Arrakis Therapeutics
Arrakis Therapeutics

Waltham, MA, US

Board Member· Board
Attralus
Attralus

San Francisco, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Richard Gaster's Career

Stargazer Pharmaceuticals
Stargazer Pharmaceuticals
Series A$94.2M62018Boston, MA, US
Board Member· Board

Leadership at Stargazer Pharmaceuticals

Houman HemmatiHouman HemmatiCo-Founder
Silvia RagnoSilvia RagnoCo-Founder
Aeovian Pharmaceuticals
Aeovian Pharmaceuticals
Series A$37.8M132012San Francisco, CA, US
Board Member· Board

Leadership at Aeovian Pharmaceuticals

Brian KennedyBrian KennedyFounder
Allison HulmeAllison HulmeCEO

Similar to Aeovian Pharmaceuticals

Azevan PharmaceuticalsAzevan PharmaceuticalsBethlehem, PA, USPharmaceuticalsest. 1999Azevan PharmaceuticalsBethlehem, PA, US · est. 1999

Azevan Pharmaceuticals develops therapeutic drugs for mood, behavior, anxiety, and stress disorders in the US.

Seed · $2.2M5
Avalyn PharmaAvalyn PharmaSeattle, WA, USPharmaceuticalsest. 2011Avalyn PharmaSeattle, WA, US · est. 2011

Avalyn Pharma Inc.: Developing innovative therapies for Idiopathic Pulmonary Fibrosis.

Series C · $272.5M27
Aria PharmaceuticalsAria PharmaceuticalsPalo Alto, CA, USPharmaceuticalsest. 2014Aria PharmaceuticalsPalo Alto, CA, US · est. 2014

Aria Pharmaceuticals: Pioneering novel therapies for complex diseases in preclinical stages.

Series B · $14.3M38
Arrakis Therapeutics
Arrakis Therapeutics
Series B$113M1212015Waltham, MA, US
Board Member· Board

Leadership at Arrakis Therapeutics

Jennifer PetterJennifer PetterCo-Founder
Russell PetterRussell PetterCo-Founder
Jakob LovenJakob LovenBoard Member
Katrine BosleyKatrine BosleyBoard Member
Michael GilmanMichael GilmanCEO

Similar to Arrakis Therapeutics

Remix TherapeuticsRemix TherapeuticsWatertown, MA, USTherapiesest. 2018Remix TherapeuticsWatertown, MA, US · est. 2018

Remix Therapeutics: A biotech firm innovating small molecule therapies to revolutionize disease treatment.

Series D · $211M71
ReviR TherapeuticsReviR TherapeuticsSan Francisco, CA, USMedicines, Therapeuticsest. 2021ReviR TherapeuticsSan Francisco, CA, US · est. 2021

ReviR Therapeutics: A genomics-based platform for developing innovative RNA-targeting medicines.

Seed · $20M27
Adarx PharmaceuticalsAdarx PharmaceuticalsSan Diego, CA, USTherapeuticsest. 2019Adarx PharmaceuticalsSan Diego, CA, US · est. 2019

ADARx Pharmaceuticals: Pioneering in mRNA base editing for genetic medicine solutions.

Series C · $332M50
858 Therapeutics858 TherapeuticsSan Diego, CA, USDrug Discoveryest. 2019858 TherapeuticsSan Diego, CA, US · est. 2019

858 Therapeutics: Innovating small molecule drugs for oncology, focusing on RNA regulation and immune response.

Series A · $80.1M27
Attralus
Attralus
Series B$141.2M292019San Francisco, CA, US
Board Member· Board

Leadership at Attralus

Mark TimneyMark TimneyBoard Member
Jake BauerJake BauerBoard Member
Jonathan WallJonathan WallCo-Founder
Spencer GuthrieSpencer GuthrieFounder & CEO

Similar to Attralus

AltPepAltPepSeattle, WA, USBiotech, Therapeuticsest. 2018AltPepSeattle, WA, US · est. 2018

AltPep: A biomedical startup innovating in amyloid disease treatment, focusing on Alzheimer's.

Series B · $76M24
Aurion BiotechAurion BiotechSeattle, WA, USBiotech, Therapiesest. 2021Aurion BiotechSeattle, WA, US · est. 2021

Aurion Biotech: Clinical-stage biotech firm pioneering advanced therapies to cure blindness.

Late Stage Private · $120M55
AdrxAdrxThousand Oaks, CA, USDrug Discoveryest. 2013AdrxThousand Oaks, CA, US · est. 2013

ADRx, Inc.: A California-based biopharmaceutical firm innovating novel drugs for amyloid diseases.

Series A · $24.3M9
Amylyx PharmaceuticalsAmylyx PharmaceuticalsCambridge, MA, USTherapeuticsest. 2014Amylyx PharmaceuticalsCambridge, MA, US · est. 2014

Amylyx Pharmaceuticals: A global biopharmaceutical firm innovating therapies for ALS and neurodegenerative diseases.

Public · $448.5M262

Richard Gaster's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Richard Gaster

Ethan BatraskiEthan BatraskiBoard Member · DecodableBrian AscherBrian AscherBoard Member · AwarepointCami SamuelsCami SamuelsBoard Member · Carmenta BioscienceRichard WarburgRichard WarburgBoard Member · Transparency Life SciencesMike TyrrellMike TyrrellBoard Member · HappierStuart NagaeStuart NagaeBoard Member · CivicEye